Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endothall is a synthetic small molecule herbicide primarily used for the control of aquatic and terrestrial weeds. Chemically known as 7‑oxabicyclo[2.2.1]heptane‑2,3‑dicarboxylic acid (C8H10O5), it acts as a contact herbicide that inhibits plant protein phosphatases—specifically protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A)—disrupting essential cellular processes such as respiration and synthesis of proteins and lipids in plants[4][5]. It is available in several formulations including dipotassium salt (e.g., Aquathol) and monoamine salts (e.g., Hydrothol 191), with each formulation varying in efficacy against different plant species and toxicity to aquatic organisms[4][6]. Endothall degrades rapidly by microbial action in water environments within about one to two months[6][8]. It is not considered neurotoxic or mutagenic nor likely to be carcinogenic to humans at environmental exposure levels; however acute overexposure can cause depressed breathing or heart rate while chronic exposure may affect organ weights of the stomach or intestine[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endothall.